Review Article

Proposed drug interventions for SARS CoV 2 infection

Pranshu Mehta*, Bharathi M. B.

Department of E. N. T., JSS Hospital, JSSAHER, Mysore, Karnataka, India

Received: 01 April 2020
Accepted: 03 April 2020

*Correspondence:
Dr. Pranshu Mehta,
E-mail: drpranshumehta@gmail.com

ABSTRACT

As the pandemic has already taken lots of lives across the globe, there’s an urgent need for finding treatment options that might help in protection of infected people by either slowing or preventing the progression of the disease. It’s important to understand the structure of virus, the mechanism by which it enters the host cell, replicates and infects other cells causing progression of the disease. This article focuses on use of already available and approved drugs for treatment of corona virus based on their mechanism of action and the structure and the life cycle of the virus.

Keywords: Corona virus treatment, Covid 19 drug intervention, Covid 19 treatment

INTRODUCTION

As the pandemic has already taken lots of lives across the globe, there’s an urgent need for finding treatment options that might help in protection of infected people by either slowing or preventing the progression of the disease. It’s important to understand the structure of virus, the mechanism by which it enters the host cell, replicates and infects other cells causing progression of the disease.

It has been noticed that the SARS CoV 2 virus has 82% nucleotide identity to the SARS CoV 1 virus and 89% to the bat SARS-like-CoVZXC21.1 Structurally corona viruses contains S protein, M proteins, E protein and N protein. S protein or the spike protein (s1 and s2), is a trimeric Class I fusion protein plays a role in attachment of virus to host cell, uses its N terminal for the same.3,4 M protein the membrane protein, it is the most abundant protein, has a large C terminal and a small N terminal and is responsible for providing shape to the virus.5,6 E protein is thought to be a transmembranous protein responsible for release of new formed viruses, in SARS CoV it is supposed to play an important role in pathogenicity.7,8 N protein is present in Nucleocapsid and has two separate domains, the N terminal and C terminal domain (NTD and CTD), both of these bind to RNA and are important in tethering the RNA to the RTC (replication-transcription complex) and for packaging the genome into the new capsids.9,12

Apart from the mentioned ones, another protein called the HE (hemagglutinin esterase) might also be present in some, it binds to saelic acid on host cell surface glycoproteins and can show acetyl esterase activity, may help S protein in attaching to the cell.13

STRUCTURE

It is an encapsulated virus with non segmented positive sense single strand RNA.

Similar to the SARS CoV 1 virus it appears to be a part of beta group of sub family coronaviridae belonging to coronavirinae family of viruses which belongs to the Nidovirales order.2
GENETIC STRUCTURE AND GENOMIC REPLICATION

The RNA has 5’ cap structure and 3’ poly A tail that enables it to act as messenger RNA and it can be used to translate proteins. It contains sequences which code for nsps (non-structural proteins) which are located in the replicase gene and occupies the majority of the genome. It also has some regions which remain untranslated called as UTR (untranslated regions), and these are located on both 5’ and 3’ ends. TRS (transcriptional regulatory sequences) are present in the initial part of all structural and accessory genes are important for the expression of the same.

RNA can directly translate polyprotein 1a and 1b (pp1a/pp1ab), which encodes nsps forming RTC (replication-transcription complex) in vesicles produced by ERGIC (endoplasmic reticulum golgi intermediate compartment).1

IMPORTANT PHASIS IN VIRAL CYCLE

1. Attachment and entry into the cells
2. Replicase protein expression
3. Genome replication and transcription
4. Assembly of constituent proteins and genome to form virus
5. Release of viruses to ECF or directly to other cells

Authors will now focus only on important aspects where drugs might act and help in preventing spread or progression of disease in all of the above mentioned phases (Figure 1).

Attachment and entry into the cells

Corona viruses attachment starts with interaction of the S protein with the surface receptors, the receptor binding domains (RBD) are loaded on S1 and fusion sequence on S2. There are different receptors like DPP4, ACE2, CEACAM1, APN which are used by different corona viruses. SARS CoV 2 uses ACE 2 receptor. However, entry can occur in absence of the enzymatic domain of these receptors.3,14,16

Proposed intervention point A

For attaching to cells, HE protein also helps, it binds to sialic acid on host cell surface, which is a part of glycoproteins. Sialic acid for being available for HE needs to be cleaved from glycoproteins which is carried out by neuroaminidases.

Proposed intervention point B

After binding the virus needs to access the cytoplasm of the host cell. The S protein is cleaved twice, first cleavage is done between S1 and S2, separating both and is carried out by proteases like CATHEPSIN leading to fusion of the membranes. Second occurs within S2, exposing the fusion peptide. This fusion peptide inserts into the membrane followed by joining of 2 heptad repeats forming a anti parallel 6 helical bundle/bridge through which the cytosol, its contents and the viral genome enters the host cell.3,14

Important

The first cleavage is carried by acid dependant protease - cathepsin, the second cleavage of S2 occurs within Acidified lysosomes.

Proposed intervention point C

Replicase protein expression

The RNA genome translates to produce pp1a and pp1b by using frame shift mechanism aided by pseudoknot bocks. Once translation is over, the resultant polyprotein needs to cleaved into its constituents. It is done by proteases like Plpro and Mpro. The cleavage and production of individual nsps are responsible for decrease and altered innate immune response.17-20 The Plpro can alter and decrease Ub-dependent cellular responses to viral infection.21

Proposed intervention point D

Genome replication and transcription

RNA replication starts following the translation, it produces both genomic and sub genomic (negative sense RNA) fragments. The RNA polymerase recognises leader sequences of TRS (TRS L) and starts replication however
it stops at at particular TRS B (body), and starts synthetising the sub genomic negative sense RNA fragments as well.22,23 The N protein tightly binds the RNA in a bead on string pattern, two specific substrates have been identified on RNA for N protein, these are TRSs and genomic packaging signal.24,25

**Proposed intervention point E**

**Assembly of constituent proteins and genome to form virus**

After replication of genome is completed, structural proteins are translated, S, E, M and are incorporated into the Endoplasmic reticulum (ER) from where they pass along the ERGIC (endoplasmic reticulum golgi intermediate compartment).26,27 N protein which is covering the genome is bud into the membrane of vesicles containing structural proteins.29 M and E proteins function together to form envelope, E protein also plays a role in release of viruses by altering host secretory pathways.30,31(Figure 5).

**Release of viruses to ECF or directly to other cells**

Once the virions are ready they are transported within the vesicles to the cell membrane and by exostosis it allows the newly formed viruses to spread to extra cellular space, where it can be detected and can also infect other cells.

**Important**

The glycosylation in golgi apparatus and transport requires acidic environment and be altered due to presence of basic substances.31

**Proposed intervention point F**

However in some cases the S protein can directly attach to adjacent cell forming a cytoplasmic connection which can be used for direct transfer of encapsulated virion to neighbouring cells without being spilled in extra cellular space and without being detected.

**Proposed intervention point G**

**Possible drug interventions**

Already few drugs have been used in various parts of the world with uncertainty, here try to provide list of drugs and their mechanism by which they may prevent the progression of disease.

**Oseltamavir**

It is a viral neuraminidase inhibitor, used in viral infections where viruses use neuroaminidase to bind to glycoproteins of host cell membrane for splitting sialic acid and releasing the new viral progeny into extracellular space.

In corona virus, the main effect could be at the binding site. Oseltamavir may prevent formation of sialic acid on surface which is required by HE protein for helping S protein in attaching to host cell.

**At intervention point B**

**Hydroxychloroquine / chloroquine**

It is a 4-Aminoquinoline, used as anti malarial drug. It gets accumulated in lysosomal vecuoles of parasite causing altered heme polymerisation leading to accumulation of toxic heme and death.

In corona virus - The affinity of drug to accumulate in higher concentration in LUNGS (100 folds), specifically lysosomes and endosomes can be used.

It is basic and can alter the pH of the endosomes where the splitting of fusion protein in S2 of corona virus takes place and can prevent further fusion of virus and host cell membranes.

**At intervention point C**

It can also be accumulated in vecuoles formed by golgi apparatus and alter the pH, golgi apparatus requires acidic pH for glyosylation and transport and hence the viral products once formed can be prevented form being assembled and transported to other cells (Figure 2) (Figure 4).

![Figure 2: Attachment of S protein and cleavage of S1 and S2.](image)
and exposed sites of Plpro protease and Mpro of coronavirus and HIV 1 aspartic protease (Figure 3).

![Figure 3: Expression of replicase gene.](image)

**At intervention point F**

**Protease inhibitor**

Anti viral drugs used to treat HIV infections, they bind to the proteases that help in splitting of polyproteins in the vecuoles of ERGIC.  

![Figure 4: Splitting of Polyprotein 1a and 1b by protease.](image)

In corona virus - The similarity of HIV 1 aspartic proteases and Candida albicans Sap2 has already been demonstrated based on one or more substrate site similarity and hence the HIV protease inhibitors are known to act against other enzymes as well.  

Response in patients with corona points the need for mapping the structural similarity between substrate sites and-exposed sites of Plpro protease and Mpro of corona virus and HIV 1 aspartic protease (Figure 3).

**At intervention point D**

**Azithromycin (macrolides)**

It is a macrolide that binds to 50s subunit of bacterial ribosome and interferes with translation. The macrolide binding site is composed primarily of RNA. Two segments of 23S rRNA, the central loop of domain V and the loop of hairpin 35 from domain II, are believed to be the major components of the drug binding site on the ribosome.  

In corona virus - The binding of N protein to RNA via its N terminal has shown to be linked with high amount of Lysine and Arginine residues that binds to the RNA of the virus. Inside the N Terminal Domain of N protein of SARS-CoV, positively charged lysine and arginine residues have been proposed that bind a 32 nucleotide stem-loop structure located at the 3' end of the SARS-CoV RNA genome.  

So Azithromycin can bind to the binding site rich in lysine and arginine on the N terminal domain of N protein of corona virus preventing it to bind to RNA and preventing the expression of replicase gene (Figure 2).

**ACE inhibitors**

Bind to angiotensin converting enzymes in circulation as well as tissue proteins. Highly lipophilic variants like moexipril, ramipril show more affinity for tissue proteins.
In corona virus - They can work by 2 mechanisms, ace inhibitors will bind to ACE 2 receptors that reduces less number of ACE 2 proteins available for identification by virus.

The inhibition however will later lead to up regulation of ACE 2 expression, which will be helpful in patients in ARDS, it will prevent further progression of ARDS towards fibrosis by inhibiting of signaling pathways involved in tissue fibrosis and will also have additional benefits like cardioprotective and nephroprotective affect.39,40 (Figure 1).

At intervention point A

\[ \text{NaHCO}_3 \text{ Nebulisation (in ARDS cases)} \]

\[ \text{NaHCO}_3 \text{ (sodium bicarbonate) - The airway acidifies in a variety of inflammatory lung diseases, airway alkalization improves absorption of cationic bronchodilators, such as albuterol and tiotropium, both in airway epithelia and smooth muscle cells.} \]

In corona virus - In cases of ARDS, pulmonary as well as lactic acid acidosis can occur, nebulisation even in absence of acidosis might be helpful by creating basic pH in the airway which hampers ACID dependant protease (cathepsin) to cleave S1 protein for attachment.

At intervention point A

\[ \text{Metabolisation of various drugs} \]

1. Oseltamivir is activated in liver but excreted via urine.42
2. Hydroxychloroquine is metabolised in liver by cytochrome P450 isoenzyme CYP2D6.43
3. Lopinavir is metabolised exclusively by cytochrome P450 isoenzyme CYP3A and ritonavir inhibits the same and hence is used with lopinavir.44
4. Ramipril is metabolised by liver and urine both to glucouronate conjugate in liver and diketopoperazine derivative in kidneys and mostly is excreted by urine.45
5. Azithromycin is metabolised by liver but does not induce or affect any other medication.46

A combination drug therapy based on multiple target sites might prove to be helpful in preventing further damage by suppressing the disease progression.

A combination of some of the drugs mentioned above might prove helpful severe patients whereas in mild cases drugs like azithromycin and hydroxychloroquine, either alone or in combination may prevent development of complications. Tab Azithromycin might also prove to be helpful as a prophylactic drug in patients with contact or infected patients without symptoms as it will prevent expression of replicase gene.

CONCLUSION

This article focuses on use of already available and approved drugs for treatment of corona virus based on their mechanism of action and the structure and the life cycle of the virus. Further research needs to be done for developing drugs with specific action against the novel corona virus, which could be targeted either to S protein receptor binding site, or against Plpro protease inhibitor of the virus.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not Required

REFERENCES

1. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.
2. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) In: StatPearls Publishing;2020.
3. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801-11.
4. Collins AR, Knobler RL, Powell H, Buchmeier MJ. Monoclonal antibodies to murine hepatitivs virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell--cell fusion. Virology. 1982;119(2):358-71.
5. Nal B, Chan C, Kien F, Siu L, Tse J, Chu K, et al. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. J General Virol. 2005;86(Pt5):1423-34.
6. Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11-22.
7. Godet M, L’Haridon R, Vautherot JF, Laude H. TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions. Virology. 1992;188(2):666-75.
8. Nieto-Torres JL, Dediego ML, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS pathogens. 2014;10(5):1004077.
9. Chang CK, Sue SC, Yu TH, Hsieh CM, Tsai CK, Chiang YC, et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomedical Sci. 2006;13(1):59-72.
10. Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. J Virol. 2009;83(14):7221-34.
11. Kuo L, Masters PS. Functional analysis of the murine coronavirus genomic RNA packaging signal. J Virol. 2013;87(9):5182-92.
12. Sturman LS, Holmes KV, Behnke J. Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid. J Virol. 1980;33(1):449-62.
13. Lissenberg A, Vrolijk MM, van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier PJ, et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. J Virol. 2005;79(24):15054-63.
14. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(14):5871-6.
15. Kim J, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, et al. Effect of Renin-Angiotensin System Blockade in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study. Korean J Crit Care Med. 2017;32(2):154-63.
16. Pines A, Fisman EZ. ACE Inhibition with Moexipril. America J Cardiovasc Drugs, 2003;3(5):351-60.
17. Araki K, Gangappa S, Dillehay DL, Rouse BT, Larsen CP, Ahmed R. Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. J Exp Med. 2010;207(11):2355-67.
18. Brierley I, Digard P, Inglis SC. Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell. 1989;57(4):537-47.
19. Baranov PV, Henderson CM, Anderson CB, Gesteland RF, Atkins JF, Howard MT. Programmed ribosomal frameshifting in decoding the SARS-CoV genome. Virology. 2005;332(2):498-510.
20. Mielech AM, Chen Y, Mesecar AD, Baker SC. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deIS Glylating activities. Virus research. 2014 Dec 19;194:184-90.
21. Baez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21-38.
22. Sethna PB, Hofmann MA, Brian DA. Minus-strand copies of replicating coronavirus mRNAs contain antileaders. J Virol. 1991;65(1):320-5.
23. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol. 2007;81(1):20-9.
24. Molenkamp R, Spaan WJ. Identification of a specific interaction between the coronavirus mouse hepatitis virus A59 nucleocapsid protein and packaging signal. Virology. 1997;239(1):78-86.
25. Kuo L, Masters PS. Functional analysis of the murine coronavirus genomic RNA packaging signal. J Virol. 2013;87(9):5182-92.
26. Krijnse-Locker J, Ericsson M, Rottier PJM, Griffiths G. Characterization of the budding compartment of mouse hepatitis virus: Evidence that transport from the RER to the golgi complex requires only one vesicular transport step. J Cell Biol. 1994;124(1):55-70.
27. Tooze J, Tooze S, Warren G. Replication of coronavirus MHV-A59 in sac- cells: determination of the first site of budding of progeny virions. Europ J Cell Biol. 1984;33(2):281-93.
28. de Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005;64:165-230.
29. Bos EC, Luytjes W, van der Meulen HV, Koerten HK, Spaan WJ. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology. 1996;218(1):52-60.
30. Ye Y, Hogue BG. Role of the coronavirus E viroporin protein transmembrane domain in virus assembly. J Virol. 2007;81(7):3597-607.
31. Maeda Y, Kinoshita T. The Acidic Environment of the Golgi Is Critical for Glycosylation and Transport. Glycobiology, 2010;495-510.
32. Solitto AR, MacKeigan JP. Leaving the lysosome behind: novel developments in autophagy inhibition. Future Med Chem. 2016;8(1):73-86.
33. Chinnapaiyan S, Parira T, Dutta R, Agudelo M, Morris A, Nair M, et al. HIV Infects Bronchial Epithelium and Suppresses Components of the Mucociliary Clearance Apparatus. PLoS One. 2017;12(1):e0169161.
34. Calugi C, Guarna A, Trabocchi, A. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicansinhibitors. J Enzyme Inhibition and Med Chem, 2012;28(5):936-43.
35. Garza-Ramos G, Xiong L, Zhong P, Mankin A. Binding site of macrolide antibiotics on the ribosome: new resistance modification identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001;183(23):6898-907.
36. Lott BB, Wang Y, Nakazato T. A comparative study of ribosomal proteins: linkage between amino acid distribution and ribosomal assembly. BMC Biophys. 2013;6(1):13.
37. McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991-3018.
38. Huang Q, Yu L, Petros AM, Gunasekera A, Lui Z, Xu N, et al. Structure of the N-terminal RNA-
binding domain of the SARS CoV nucleocapsid protein. Biochemistry. 2004;43(20):6059-63.
39. Colafella KM, Uijl E, Danser J. Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches. Encyclopedia of Endocrine Diseases. 2019;523-30.
40. Turner AJ. ACE2 Cell Biology, Regulation, and Physiological Functions. The Protective Arm of the Renin Angiotensin System. RAS. 2015;185-9.
41. Kis A, Toth LA, Kunos L, Vasas S, Losonczy G, Mendes E et al. The effect of airway alkalization by nebulized sodium bicarbonate on airway blood flow. Eur Respirat J. 2012;40:P2143.
42. Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010;65;2(2):ii5-10.
43. Somer M, Kallio J, Pesonen U, Pyykkö K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol. 2000;49(6):549-54.
44. Mallayasamy S, Penzak SR. Pharmacogenomic Considerations in the Treatment of HIV Infection. Pharmacogenomics. 2019;227-45.
45. Meisel S, Shamiss A, Rosenthal T. Clinical Pharmacokinetics of Ramipril. Clinical Pharmacokinetics. 1994;26(1):7-15.
46. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrobial Chemother. 1996 Jun 1;37(suppl_C):133-42.

Cite this article as: Mehta P, Bharathi MB. Proposed drug interventions for SARS CoV 2 infection. Int J Res Med Sci 2020;8:1950-6.